Navigation Links
Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
Date:11/7/2012

JERUSALEM, Israel, November 6, 2012 Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012. QNASL is a recently approved "dry" nasal aerosol corticosteroid that treats seasonal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

Findings from one clinical study being presented at the meeting highlight the nasal symptom improvement and efficacy profile of QNASL in children ages 6-11 with seasonal allergic rhinitis (SAR), while others reinforce ocular safety, appropriate dosing and device performance.

On March 23, 2012, the U.S. Food and Drug Administration (FDA) approved QNASL. The product became available to patients by prescription in April 2012, making it the first marketed nonaqeous or "dry" nasal aerosol product in a category that reports annual sales of $2.5 billion. QNASL is delivered as a once-daily, nonaqueous aerosol that uses an environmentally friendly propellant (HFA) and contains a built-in dose counter.

"QNASL has provided an alternative therapy for patients suffering from allergic rhinitis," said Dr. William Storms, MD, practicing allergist, clinical professor at the University of Colorado Health Sciences Center and founder of the William Storms Allergy Clinic in Colorado Springs, CO. "The dry mode of delivery of QNASL, along with the performance and functionality of the device, offers patients a safe and effective way to manage and control their nasal allergy symptoms. The data to be presented at ACAAI this year further demonstrate the efficacy profile of QNASL, especially among the pediatric population and confirm the product's ocular safety profile in adolescents and adults."

The following QNASL (beclomethasone dipropionate) data will be presented during poster sessions on Saturday, November 10 from 12:30 1:30 p.m. PST and Sunday, November 11 from 12:00 1:00 p.m. PST in Hall C (first floor) of the Anaheim Convention Center at the ACAAI Annual Meeting:

  • #P314: Device and Integrated Dose Counter Performance of Beclomethasone Dipropionate Nasal Aerosol During Daily Use

  • #P329: Nasal Symptom Improvement Following Once-Daily Treatment With Beclomethasone Dipropionate Nasal Aerosol (80 g or 160 g) in Children With Seasonal Allergic Rhinitis

  • #P330: Efficacy, Safety, and Optimal Dose Selection of Beclomethasone Dipropionate Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

  • #P331: Evaluation of Ocular Safety Following Long-Term Treatment With Beclomethasone Dipropionate Nasal Aerosol in Subjects With Perennial Allergic Rhinitis

  • #P325: Nasal Deposition of Beclomethasone Dipropionate Nasal Aerosol Versus Fluticasone Propionate and Mometasone Furoate Aqueous Nasal Sprays

"The data to be presented at ACAAI provide additional evidence that QNASL is a generally well-tolerated and effective treatment option for people suffering with seasonal and year-round nasal allergies," said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. "We are committed to the development of novel therapies to help the millions of Americans who suffer from allergic rhinitis effectively manage and control their burdensome symptoms."


'/>"/>
Contact: Denise Bradley
denise.bradley@tevapharm.com
215-591-8974
Teva North America


Source:Eurekalert


Related medicine news :

1. Medical care presents update on pharmaceutical health services research
2. Results of the STEMI-RADIAL trial presented at TCT 2012
3. Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
4. Results of the XIMA trial presented at TCT 2012
5. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
6. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
7. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
8. Results of the PC trial presented at TCT 2012
9. Results of the POSEIDON trial presented at TCT 2012
10. 1-year results of ADAPT-DES presented at TCT 2012
11. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... communities in the greater Dallas, Miami, and Raleigh regions, is organizing an extended ... overcome a rare and deadly chromosome abnormality. , After struggling since birth with ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
Breaking Medicine Technology: